A Strong Launch For Sarepta’s Elevidys, But Future Hinges On FDA Decision

Strong demand from physicians and families of boys with Duchenne has seen a rapid take-off in sales of the $3.2m gene therapy – but the FDA will have the final say on the product's future after a failed Phase III study.